NCT03971409 2026-04-17
InCITe
University of California, San Francisco
Phase 2 Active not recruiting
Clinical Trials
39 trialsNCT03678883 2026-04-03
9-ING-41 in Patients With Advanced Cancers
Actuate Therapeutics Inc.
Phase 2 Active not recruiting
NCT05748834 2026-03-20
Study of Tucatinib and Doxil in Participants With Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Metastatic Breast Cancer
SCRI Development Innovations, LLC
Phase 2 Recruiting
NCT04293393 2026-03-12
CARABELA
Spanish Breast Cancer Research Group
Phase 2 Active not recruiting
NCT03301350 2026-02-13
Neoadjuvant Carbo/Paclitaxel Followed by Doxorubicin/Cyclophosphamide in Breast Cancer
University of Wisconsin, Madison
Phase 2 Completed
NCT01818063 2025-04-30
Carboplatin and Combination Chemotherapy With or Without Veliparib in Treating Patients With Stage IIB-IIIC Breast Cancer
Thomas Jefferson University
Phase 2 Completed
NCT02299999 2025-01-15
SAFIR02_Breast
UNICANCER
Phase 2 Active not recruiting
NCT03164993 2024-10-15
ALICE
Oslo University Hospital
Phase 2 Completed
NCT03409198 2024-10-15
ICON
Oslo University Hospital
Phase 2 Completed
NCT01990352 2023-11-21
Correlate BRCA1 Protein Expression With Response to DNA Damaging Chemotherapy
University of Arizona
Phase 2 Terminated
NCT00499083 2023-09-29
Paclitaxel, Cyclophosphamide & Doxorubicin, Autologous Dendritic Cells & Surgery in Stage II/III Breast Cancer (Women)
University of Nebraska
Phase 2 Completed
NCT03712956 2023-09-21
CAELYX® as Adjuvant Treatment in Early Stage Luminal B Breast Cancer BREAST CANCER
European Institute of Oncology
Phase 2 Unknown
NCT00665457 2023-09-13
Biomarkers in Women Receiving Chemotherapy & Celecoxib for Stage II or Stage III Breast Cancer Removable by Surgery
University of Nebraska
Phase 2 Terminated
NCT00258960 2023-04-04
Caelyx, Cyclophosphamide and Herceptin in Patients With Metastatic Breast Cancer
Spanish Breast Cancer Research Group
Phase 2 Completed
NCT02315196 2023-03-29
Pegylated Liposomal Doxorubicin Hydrochloride and Carboplatin Followed by Surgery and Paclitaxel in Treating Patients With Triple Negative Stage II-III Breast Cancer
Rutgers, The State University of New Jersey
Phase 2 Active not recruiting
NCT05386524 2023-02-16
Sintilimab and Bevacizumab Biosimilar Combined With PLD in mTNBC
Fudan University
Phase 2 Unknown
NCT00608972 2023-02-08
Phase II Trial of Doxil, Carboplatin, Bevacizumab in Triple Negative Untreated Metastatic Breast Cancer
Rutgers, The State University of New Jersey
Phase 2 Completed
NCT05346107 2022-04-26
PLD-cyclophosphamide-Nab-P Continuously Combined With Dual HER2 Blockage for HER2-positive Breast Cancer
Xijing Hospital
Phase 2 Unknown
NCT05097248 2021-10-28
Camrelizumab in Combination With PLD and Losartan in Patients With TNBC Who Have Received ≦ 1 Line of Chemotherapy
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Phase 2 Unknown
NCT00687440 2018-07-03
A Study to Determine the Activity of Caelyx With Trastuzumab and Docetaxel in the Treatment of Metastatic Breast Cancer (Study P03679)
Merck Sharp & Dohme LLC
Phase 2 Completed
NCT02953184 2017-12-29
Marched Pair Study Conventional Doxorubicin(DOX) Versus Pegylated Liposomal Doxorubicin(PLD) Neoadjuvant Chemotherapy
Jilin University
Phase 2 Unknown
NCT01669239 2017-11-06
Opti-HER
SOLTI Breast Cancer Research Group
Phase 2 Completed
NCT00563953 2017-10-12
CAPRICE
SOLTI Breast Cancer Research Group
Phase 2 Completed
NCT00550771 2017-06-07
Phase II Trial to Compare the Safety of Two Chemotherapy Plus Trastuzumab Regimens as Adjuvant Therapy for HER2-positive Breast Cancer (Study P05048)
Merck Sharp & Dohme LLC
Phase 2 Completed
NCT00303108 2016-11-03
Doxil & Carboplatin Plus HER2+ in Metastatic Breast Cancer
US Oncology Research
Phase 2 Completed
NCT00635050 2016-07-14
Therapy for Locally Advanced Breast Cancer Using Doxil, Paclitaxel, and Cyclophosphamide With Avastin
University of Alabama at Birmingham
Phase 2 Completed
NCT00284336 2014-12-09
Caelyx Adjuvant in Elderly Breast Cancer
Universitaire Ziekenhuizen KU Leuven
Phase 2 Completed
NCT00691912 2014-09-03
MyoPac
University of Magdeburg
Phase 2 Terminated
NCT00004888 2014-05-23
Combination Chemotherapy With or Without Trastuzumab in Treating Women With Metastatic Breast Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT00193037 2013-07-31
Doxorubicin HCI Liposome Injection Versus Weekly Docetaxel in Patients First Relapse Metastatic Breast Cancer
SCRI Development Innovations, LLC
Phase 2 Completed
NCT00431795 2013-02-13
Randomized Phase II Study of Epirubicin vs Caelyx in Pretreated Metastatic Breast Cancer
Hellenic Oncology Research Group
Phase 2 Terminated
NCT00434031 2012-07-30
CETRA
National Cancer Institute, Naples
Phase 2 Withdrawn
NCT01206881 2011-07-04
Neoadjuvant Pegylated Liposomal Doxorubicin and Cyclophosphamide +/- Trastuzumab Followed by Docetaxel in Breast Cancer
Herlev Hospital
Phase 2 Completed
NCT00524810 2011-06-30
Liposomal Doxorubicin and Docetaxel in Metastatic Breast Cancer
ARCAGY/ GINECO GROUP
Phase 2 Completed
NCT00518583 2010-01-15
Phase II Study in Patients With Operable Breast Cancer
Aptium Oncology Research Network
Phase 2 Unknown
NCT00465673 2009-08-06
Liposomal Doxorubicin (Lipo-Dox) in Patients With Brain Metastasis From Breast Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 2 Terminated
NCT00159094 2008-06-02
A Trial of Doxil and Multiday Vinorelbine in Patients With Metastatic Breast Cancer
Hematology Oncology Consultants
Phase 2 Unknown
NCT00250874 2005-11-08
Myocet, Docetaxel & Trastuzumab as 1st Line Treatment of Patients With HER-2/Neu Positive Metastatic Breast Cancer
Zeneus Pharma
Phase 2 Unknown
NCT00006433 2005-06-24
Phase I/II Trial of Doxil and Hyperthermia for Breast Cancer Patients With Chest Wall Recurrence or Stage IV Disease With Locally Advanced Breast Cancer
National Center for Research Resources (NCRR)
Phase 2 Unknown